Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1892815 | 0.81 | EGFR (0.31) | EGFRERBB2 | |
| SCHEMBL6383645 | 0.80 | — | — | |
| SCHEMBL3148473 | 0.76 | — | — | |
| SCHEMBL31586775 | 0.76 | — | — | |
| Bicarbonate SCHEMBL9083427 | 0.71 | ALDH1A1 (0.44) | ALDH1A1TSHR | |
| Bicarbonate SCHEMBL27364872 | 0.71 | ALDH1A1 (0.44) | ALDH1A1TSHR | |
| SCHEMBL9746895 | 0.71 | — | — | |
| SCHEMBL15241254 | 0.70 | — | — | |
| Acetic Acid SCHEMBL775971 | 0.69 | ALDH1A1 (0.42) | ALDH1A1TSHR | |
| Acetic Acid SCHEMBL5166708 | 0.69 | ALDH1A1 (0.42) | ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2253620-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2010-11-24 | — | — | EP | claimed |
| EP-1950201-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2008-07-30 | — | — | EP | claimed |
| EP-1000039-B1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | WYETH CORP (US) | 2004-06-09 | — | — | EP | claimed |
| EP-1117649-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | claimed |
| US-6251912-B1 | Substituted quinazoline derivatives | AMERICAN CYANAMID COMPANY | 2001-06-26 | — | — | US | claimed |
| EP-1000039-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | American Cyanamid Company (US) | 2000-05-17 | — | — | EP | claimed |
| WO-2000018740-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
| WO-1999009016-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. | 2023-01-05 | — | — | US | disclosed |
| WO-2021035096-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | KUMQUAT BIOSCIENCES INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| EP-2896612-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings LLC (US) | 2015-07-22 | — | — | EP | disclosed |
| EP-2253620-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH HOLDINGS LLC (US) | 2014-03-12 | — | — | EP | disclosed |
| US-RE42376-E1 | Substituted 3-cyanoquinolines | WYETH HOLDINGS CORPORATION (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2253620-A1 | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors | Wyeth Holdings Corporation (US) | 2010-11-24 | — | — | EP | disclosed |
| EP-1117649-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | American Cyanamid Company (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6251912-B1 | Substituted quinazoline derivatives | AMERICAN CYANAMID COMPANY | 2001-06-26 | — | — | US | disclosed |
| WO-2000066583-A1 | SUBSTITUTED 3-CYANO-[1.7], [1.5], AND [1.8]-NAPHTHYRIDINE INHIBITORS OF TYROSINE KINASES | AMERICAN CYANAMID COMPANY (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-1000039-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | American Cyanamid Company (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-2000018740-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 2000-04-06 | — | — | WO | disclosed |
| WO-1999009016-A1 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS TYROSINE KINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230001008-A1 | COMPOSITIONS AND METHODS FOR TARGETING CELLULAR MOLECULES | CD2BP2, CD47, CD74 | ALDH1A1 4756/4885EGFR 1892/4885ERBB2 2230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.